Stockreport

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announ [Read more]